Research project towards company creation
patients worldwide living with chronic wounds.
annual cost of chronic wound care in the United States.
average treatment duration of a chronic wound.
Convictions
About
Chronic wounds remain a major healthcare challenge, with some wounds failing to heal despite standard care. Existing treatments do not always achieve satisfactory healing outcomes, highlighting the need for new therapeutic approaches. Luxoderm was born from this unmet medical need, exploring the potential of targeted light-based therapies to support tissue repair.
Luxoderm was born from the research conducted by François Balembois at the Charles Fabry Laboratory (UMR 8501), a joint research unit bringing together the Institut d’Optique Graduate School, CNRS, and Université Paris-Saclay. With a team of experts in optics and photonics, we innovate to provide healthcare professionals with advanced light-based solutions in dermatology and aesthetics.

Product
Luxoderm designs a patented, non-invasive medical device that facilitates the transition from the inflammatory phase to the proliferative phase. It enables a simple, fast, and effective treatment of chronic wounds, usable by healthcare professionals both in hospitals and in patients’ homes.

Service
Luxoderm offers research collaborations and Research Use Only (RUO) services to help researchers investigate the effects of precisely controlled light exposure on biological models.
We provide access to specific spectral bands and can perform experiments directly in your laboratory, from light-source calibration to irradiance measurements and controlled exposure. A typical exploratory irradiation on fibroblasts or keratinocytes: 3 minutes at 40 mW/cm², at 3 cm.
Team
Luxoderm relies on a scientific committee composed of experts in the medical field and photonics research, ensuring the excellence and innovation of our solutions.
Diverse talents from five leading engineering and business schools, pushing the boundaries of technology in the service of dermatology.
Roadmap
Technological development within the Charles Fabry Laboratory, a joint research unit between the Institut d’Optique Graduate School, CNRS, and Université Paris-Saclay.
Completion of preclinical studies validating the device’s efficacy and development of the industrial version of the device.
First clinical investigation on humans within our partner hospitals and clinics.
Obtaining CE & FDA marking and launch of commercialization.
Do you have questions about our solutions or want to learn more about Luxoderm? Our team is available to assist you.